Sugi Predict

Sugi Predict / Compounds / SCHEMBL4032168

SCHEMBL4032168

SCHEMBL4032168

C#Cc1ccc(OC)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 1/20 0.49
▸ NNMT P40261 1/20 0.43
▸ CYP2A6 P11509 2/20 0.41
▸ ACACB O00763 3/20 0.40
▸ PIK3CA P42336 2/20 0.40
▸ MTOR P42345 2/20 0.40
▸ MKNK1 Q9BUB5 1/20 0.39
▸ MKNK2 Q9HBH9 1/20 0.39
▸ HAO1 Q9UJM8 1/20 0.38
▸ HSD17B1 P14061 1/20 0.38
▸ HSD17B2 P37059 1/20 0.38
▸ TUBB4A P04350 1/20 0.38
▸ TUBB P07437 1/20 0.38
▸ TUBA3C P0DPH7 1/20 0.38
▸ TUBA1B P68363 1/20 0.38
▸ TUBA4A P68366 1/20 0.38
▸ TUBB4B P68371 1/20 0.38
▸ TUBB3 Q13509 1/20 0.38
▸ TUBB2A Q13885 1/20 0.38
▸ TUBB8 Q3ZCM7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1391329 0.80 MAPT (0.47) ACACBPIK3CAMAPT
SCHEMBL17980714 0.80 ACACB (0.47) ACACBPIK3CAMKNK1MKNK2
SCHEMBL3090390 0.79 GRM5 (0.49) GRM5NNMTCYP2A6ACACBPIK3CA
SCHEMBL524681 0.79 GRM5 (0.49) GRM5NNMTCYP2A6ACACBPIK3CA
SCHEMBL3090699 0.79 GRM5 (0.49) GRM5NNMTCYP2A6ACACBPIK3CA
SCHEMBL21326764 0.79 ACACB (0.49) GRM5ACACBPIK3CA
SCHEMBL17761625 0.78 GRM5 (0.55) GRM5NNMTCYP2A6ACACBPIK3CA
SCHEMBL22031558 0.76 GRM5 (0.54) GRM5NNMTCYP2A6ACACBPIK3CA
SCHEMBL6132989 0.76 GRM5 (0.50) GRM5NNMTCYP2A6ACACBPIK3CA
SCHEMBL31044583 0.76 GRM5 (0.50) GRM5NNMTCYP2A6ACACBPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122132-A1 NITRIFICATION INHIBITORS LINCOLN UNIVERSITY (NZ) 2025-04-17 — — US claimed
EP-3990417-B1 IMPROVEMENTS IN AND RELATING TO NITRIFICATION INHIBITORS LINCOLN UNIV (NZ) 2024-03-27 — — EP claimed
US-20230202941-A1 NITRIFICATION INHIBITORS LINCOLN UNIVERSITY (NZ) 2023-06-29 — — US claimed
CN-115867525-A Improvements in and relating to nitrification inhibitors 林肯大学 2023-03-28 — — CN claimed
US-11578013-B2 Nitrification inhibitors LINCOLN UNIVERSITY (NZ) 2023-02-14 — — US claimed
US-20220153655-A1 NITRIFICATION INHIBITORS LINCOLN UNIVERSITY (NZ) 2022-05-19 — — US claimed
EP-3990417-A1 IMPROVEMENTS IN AND RELATING TO NITRIFICATION INHIBITORS Lincoln University (NZ) 2022-05-04 — — EP claimed
WO-2021242122-A1 IMPROVEMENTS IN AND RELATING TO NITRIFICATION INHIBITORS LINCOLN UNIVERSITY (NZ) 2021-12-02 — — WO claimed
US-20250122132-A1 NITRIFICATION INHIBITORS LINCOLN UNIVERSITY (NZ) 2025-04-17 — — US disclosed
CN-113620945-B RET inhibitor, pharmaceutical composition thereof and application of RET inhibitor in medicines 广东东阳光药业股份有限公司 2024-08-23 — — CN disclosed
US-11976072-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-05-07 — — US disclosed
EP-4359415-A1 DIACYLGLYERCOL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2024-05-01 — — EP disclosed
EP-3990417-B1 IMPROVEMENTS IN AND RELATING TO NITRIFICATION INHIBITORS LINCOLN UNIV (NZ) 2024-03-27 — — EP disclosed
EP-4339261-A2 IMPROVEMENTS IN AND RELATING TO NITRIFICATION INHIBITORS Lincoln University (NZ) 2024-03-20 — — EP disclosed
EP-1725544-A1 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-11-29 — — EP disclosed
EP-1689747-A1 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2006-08-16 — — EP disclosed
US-20060079519-A1 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-04-13 — — US disclosed
WO-2005090333-A1 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-09-29 — — WO disclosed
WO-2005054238-A1 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2005-06-16 — — WO disclosed
WO-2004016605-A1 2-AMINOPYRIMIDINE DERIVATIVES AS ADENOSINE A1 AND A2A RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-02-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202941-A1 NITRIFICATION INHIBITORS NOS1, NOS2, NOS3 GRM5 1650/4885NNMT 5/4885CYP2A6 525/4885
US-11578013-B2 Nitrification inhibitors NOS1, NOS2, NOS3 GRM5 1650/4885NNMT 5/4885CYP2A6 525/4885
US-20250122132-A1 NITRIFICATION INHIBITORS NOS1, NOS2, NOS3 GRM5 1650/4885NNMT 5/4885CYP2A6 525/4885
US-11976072-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK GRM5 2354/4885NNMT 1328/4885CYP2A6 4305/4885
US-20060079519-A1 Anti-cytokine heterocyclic compounds TNF, IL6, IL1A GRM5 3125/4885NNMT 2620/4885CYP2A6 892/4885
US-20220153655-A1 NITRIFICATION INHIBITORS NOS1, NOS2, NOS3 GRM5 1650/4885NNMT 5/4885CYP2A6 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.